Nucl Med Mol Imaging.
2025 Apr;59(2):154-155. 10.1007/s13139-024-00882-1.
68Ga-PSMA Uptake in Subchondral Cyst Giving a False Impression of Disease Progression after 177Lu-PSMA Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer
- Affiliations
-
- 1Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
- KMID: 2567348
- DOI: http://doi.org/10.1007/s13139-024-00882-1
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
- Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [ 161Tb]Tb-PSMA and [ 177 Lu]Lu-PSMA in Advanced Prostate Cancer Post [ 177 Lu]Lu-PSMA Failure
- [68 Ga]Ga-PSMA-11 Small Bowel Uptake in Crohn’s Disease: Revisiting the “Non-specificity” of PSMA Ligands
- Technetium 99m PSMA Superscan Mimicking a Bone Scan Gone Wrong
- 68Ga‑PSMA‑11 Uptake in Tracheal Mucus Plug – a Potential Pitfall
